Rating Change
Citigroup reiterated its Buy rating on Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) on November 03, 2026.
reiterateNASDAQ:MDGL
Citigroup Reiterates Buy Rating on Madrigal Pharmaceuticals, Inc. (MDGL)
Citigroup reiterated its Buy rating on Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) on November 03, 2026.
At publication ·
What changed
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) · reiterate
- Firm
- Citigroup
- Rating
- Buy to Buy
- Price at event
- $396.32
- Market capitalization
- $12.7B
At a glance
Key takeaways
- Citigroup reiterated its Buy rating on Madrigal Pharmaceuticals on November 3, 2026, with the stock trading at $396.32 and a market capitalization of $12.7 billion.
Market Context
Madrigal Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $396.32 with a market capitalization of $12.7B. The stock has gained 4.6% over the past 52 weeks.
Analyst coverage from Citigroup provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Madrigal Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Madrigal Pharmaceuticals, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 03, 2026 | Citigroup | Buy | N/A |
| Sep 24, 2026 | Goldman Sachs | Buy | N/A |
| Sep 23, 2026 | Citigroup | Buy | N/A |
| Aug 04, 2026 | Wolfe Research | Outperform | N/A |
| Aug 03, 2026 | Barclays | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View MDGL Stock Page
Frequently Asked Questions
What does the Buy rating mean for MDGL?
A rating of Buy from Citigroup reflects the analyst's outlook on Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MDGL forecast page.